| AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates |
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2025-04-30 13:15:37 |
Czytaj oryginał (ang.) |
| AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update |
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025 Presentations at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets Cash resources of CHF 145.7 million as of March 31, 2025 provide funding into Q1 2027 before any potential milestones Lausanne, Switzerland, April 30, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended March 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune's portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development. |
globenewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease |
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease |
globenewswire.com |
2025-04-02 10:00:00 |
Czytaj oryginał (ang.) |
| AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 |
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership. |
globenewswire.com |
2025-03-25 09:00:00 |
Czytaj oryginał (ang.) |
| ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? |
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now. |
zacks.com |
2025-03-24 18:01:11 |
Czytaj oryginał (ang.) |
| AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update |
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer's disease (AD) and DS expected in 2025 Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in AD ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson's disease (PD); further interim results in H1 2025 Cash resources of CHF 165.5 million at year end provides funding into Q1 2027, assuming no other milestones Lausanne, Switzerland, March 13, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We significantly advanced our leading position in the precision prevention of neurodegenerative diseases in 2024 through strong pipeline progress and the closing of a landmark deal with Takeda. |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know |
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-05 15:00:58 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for March 5th |
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025. |
zacks.com |
2025-03-05 09:40:25 |
Czytaj oryginał (ang.) |
| Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) |
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-13 12:36:10 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 31st |
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024. |
zacks.com |
2025-01-31 08:56:08 |
Czytaj oryginał (ang.) |
| AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients |
AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease. |
benzinga.com |
2024-11-14 12:32:49 |
Czytaj oryginał (ang.) |
| AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates |
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2024-08-06 14:25:33 |
Czytaj oryginał (ang.) |
| AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 |
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 |
globenewswire.com |
2024-07-31 12:30:00 |
Czytaj oryginał (ang.) |
| AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward |
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032. |
seekingalpha.com |
2024-07-26 19:10:34 |
Czytaj oryginał (ang.) |
| AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease |
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently initiated Phase 2b clinical trial ReTain is currently recruiting participants with preclinical Alzheimer's disease, where individuals have yet to show clinical symptoms. |
globenewswire.com |
2024-07-25 11:00:00 |
Czytaj oryginał (ang.) |
| AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 |
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024. The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET). |
globenewswire.com |
2024-05-28 11:00:00 |
Czytaj oryginał (ang.) |
| Alzheimer's vaccine licensing deal boosts AC Immune |
AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental Alzheimer's disease vaccine. |
marketwatch.com |
2024-05-13 12:47:00 |
Czytaj oryginał (ang.) |
| Why Is AC Immune (ACIU) Stock Up 45% Today? |
AC Immune (NASDAQ: ACIU ) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE: TAK ). |
investorplace.com |
2024-05-13 12:13:09 |
Czytaj oryginał (ang.) |
| AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update |
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapy ACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson's disease (PD) on track for safety and immunogenicity interim data in H2 2024 Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone Lausanne, Switzerland, May 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended March 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are thrilled to have announced today our agreement with Takeda to advance ACI-24.060 anti-Abeta active immunotherapy in Alzheimer's disease (AD). |
globenewswire.com |
2024-05-13 10:05:00 |
Czytaj oryginał (ang.) |
| AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease |
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer's disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to. |
businesswire.com |
2024-05-13 10:00:00 |
Czytaj oryginał (ang.) |